Literature DB >> 30100272

Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back.

Roy Elias1, Payal Kapur2, Ivan Pedrosa3, James Brugarolas4.   

Abstract

Entities:  

Keywords:  Checkpoint inhibitors; Hyperprogression; Immune-related adverse events; Immunotherapy; Infection; SBRT

Mesh：

Year:  2018        PMID： 30100272      PMCID： PMC7085275          DOI： 10.1016/j.clgc.2018.07.015

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  16 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

Review 2.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

3.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

Review 4.  Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.

Authors:  Dan Ishihara; Laurentiu Pop; Tsuguhide Takeshima; Puneeth Iyengar; Raquibul Hannan
Journal:  Cancer Immunol Immunother       Date:  2016-10-14       Impact factor: 6.968

5.  Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Authors:  Kevin D Courtney; Jeffrey R Infante; Elaine T Lam; Robert A Figlin; Brian I Rini; James Brugarolas; Naseem J Zojwalla; Ann M Lowe; Keshi Wang; Eli M Wallace; John A Josey; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2017-12-19       Impact factor: 44.544

6.  Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Authors:  Bernard Escudier; Robert J Motzer; Padmanee Sharma; John Wagstaff; Elizabeth R Plimack; Hans J Hammers; Frede Donskov; Howard Gurney; Jeffrey A Sosman; Pawel G Zalewski; Ulrika Harmenberg; David F McDermott; Toni K Choueiri; Martin Richardet; Yoshihiko Tomita; Alain Ravaud; Justin Doan; Huanyu Zhao; Helene Hardy; Saby George
Journal:  Eur Urol       Date:  2017-04-12       Impact factor: 20.096

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors:  E Saâda-Bouzid; C Defaucheux; A Karabajakian; V P Coloma; V Servois; X Paoletti; C Even; J Fayette; J Guigay; D Loirat; F Peyrade; M Alt; J Gal; C Le Tourneau
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.

Authors:  Ghayathri Jeyakumar; Seongho Kim; Naresh Bumma; Craig Landry; Cynthia Silski; Stacey Suisham; Brenda Dickow; Elisabeth Heath; Joseph Fontana; Ulka Vaishampayan
Journal:  J Immunother Cancer       Date:  2017-10-17       Impact factor: 13.751
View more
  3 in total

1.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Authors:  Jean-Christophe Pignon; Opeyemi Jegede; Sachet A Shukla; David A Braun; Christine E Horak; Megan Wind-Rotolo; Yuko Ishii; Paul J Catalano; Jonian Grosha; Abdallah Flaifel; Jesse S Novak; Kathleen M Mahoney; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Toni K Choueiri; Catherine J Wu; Michael B Atkins; David F McDermott; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

2.  Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.

Authors:  Viral Patel; Roy Elias; Joseph Formella; William Schwartzman; Alana Christie; Qi Cai; Venkat Malladi; Payal Kapur; Miguel Vazquez; Renee McKay; Ivan Pedrosa; Raquibul Hannan; Hans Hammers; James Brugarolas
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

3.  Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.

Authors:  Amrit S Gonugunta; Mitchell S von Itzstein; David E Gerber
Journal:  J Med Case Rep       Date:  2022-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.